long intergenic non-protein coding RNA 2022Genealiases: []
Q-omics provides the consensus-scored LINC02022 profile across patient tissues and cancer cell-line models. LINC02022 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC02022 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, LINC02022 RNA expression shows 5,246 significant pathway-activity associations, with the highest sampling consensus in LGG. Together, these results highlight UCS, BRCA, and LGG as cancer lineages where LINC02022 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02022 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02022 survival associations across molecular data types. LINC02022 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02022 RNA expression–survival associations across cancer types. High LINC02022 expression shows unfavorable associations in THCA, COAD and TGCT, but favorable associations in UCS, LUAD and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify UCS as the clearest survival context for LINC02022 RNA expression.
This table summarizes LINC02022 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02022. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02022 shows lower tumor expression in BRCA and PRAD and higher tumor expression in HNSC and KIRP. The BRCA box plot shows higher LINC02022 RNA expression in normal versus tumor tissue (log2 FC = −0.204, t-test p < 0.001).
This table shows molecular features associated with LINC02022 in patient tissues and cancer cell lines. In patient samples, LINC02022 shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set.
